Sep 8, 2020
In this episode, we discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task.
The vagaries and complexities of bringing a therapeutic drug to market through the Drug Discovery and Development (DDD) process are well known and described.
Any company that undertakes such a time-consuming, financially-burdensome, risk-laden task must have access to a myriad of experienced and professional help. The depth and breadth of expertise required includes broad business knowledge, accounting, legal, intellectual property tactics and strategy, scientific discovery, animal models, toxicology, specific disease-domain understanding, regulatory, clinical trials, manufacturing, marketing, sales and distribution skills.
By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr
If you'd like to view the original article then follow the link below:
https://www.ddw-online.com/business/p323009-the-reality-of-virtual-pharmaceutical-companies.html
You can also download the original article pdf here:
https://www.ddw-online.com/media/32/136354/(1)-the-reality-of-virtual.pdf
For more information on Drug Discovery World, head to: